BioSpace

Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T asset

Aside from RG6540, Roche also discontinued a host of other early-stage assets, including an antisense oligonucleotide for Alzheimer’s disease and a small-molecule candidate for geographic atrophy.

By BioSpace

1 min read
Roche’s pipeline trim claims Poseida’s off-the-shelf CAR T asset
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights